# Auryxia (Ferric Citrate) Therapy for In-Center and Home Dialysis Participants

> **NCT04922645** · PHASE4 · COMPLETED · sponsor: **USRC Kidney Research** · enrollment: 214 (actual)

## Conditions studied

- Hyperphosphatemia
- Anemia, Iron Deficiency
- Renal Insufficiency

## Interventions

- **DRUG:** Ferric Citrate 1 gram Oral Tablet
- **DRUG:** Standard of care phosphate-lowering therapy

## Key facts

- **NCT ID:** NCT04922645
- **Lead sponsor:** USRC Kidney Research
- **Sponsor class:** NETWORK
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-29
- **Primary completion:** 2022-09-15
- **Final completion:** 2022-09-15
- **Target enrollment:** 214 (ACTUAL)
- **Last updated:** 2022-11-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04922645

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04922645, "Auryxia (Ferric Citrate) Therapy for In-Center and Home Dialysis Participants". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04922645. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*